STAT

Opinion: The private sector is working to fight climate change. Why isn’t it doing the same to improve global health?

It is possible to end the three biggest infectious disease epidemics affecting humanity — HIV, TB, and malaria — and save millions of lives. But we need to get the…
More than 200 million people, like this south Sudanese woman, are afflicted with malaria. More vigorous global partnerships could help end the disease.

We can end the three biggest infectious disease epidemics if we want to. So why aren’t we?

That was my question to business leaders at the annual World Economic Forum in Davos, Switzerland. But it’s also a question the global health community needs to ask itself.

Two weeks ago, I met with President Emmanuel Macron of France to launch the Global Fund’s Investment, which calls for at least $14 billion to help the world get back on track to end HIV, tuberculosis, and malaria and to accelerate progress toward health and well-being for all, the United Nations . While in Davos, I called on private sector leaders to mobilize of that target.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks